BLU-5937 is a highly selective P2X3 antagonist currently being investigated for the treatment of chronic cough. touchRESPIRATORY were delighted to speak with Professor Alyn Morice (Hull York Medical School, University of Hull, Castle Hill Hospital, Yorkshire, UK) around the challenges and unmet needs in the treatment of refractory chronic cough and the aims, design and patient characteristics of the patients enrolled in the Phase 2b study (ClinicalTrials Identifier: NCT04678206).
The abstract ‘Characteristics of Participants with Refractory Chronic Cough Enrolled in A Phase 2b Trial of BLU-5937.’ (Abstract number: PA178) was presented at ERS 2022, 4–6 September, 2022.
Questions
- What are the challenges and unmet needs in the treatment of refractory chronic cough? (0:12)
- What is BLU-5937 and what is the rationale for its use in refractory chronic cough? (1:28)
- What are the aims and design of the Phase 2b study? (2:09)
- What were the patient characteristics of patients enrolled in this trial? (4:57)
- When are results from the phase 2b study expected? (6:04)
Disclosures: Alyn Morice discloses consulting for MSD; receiving grant/ research support from Merck; serving on advisory boards for MSD; receiving honoraria from MSD; and participating in speaker’s bureaus for MSD.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ERS meeting 2022.
